Catalyst Pharmaceuticals' controversial $375,000 rare autoimmune disease drug now won't face generic competition from Teva until Feb. 25, 2035, thanks to a patent settlement announced by the two companies.
The settlement follows Florida-based Catalyst's suit ...
↧